Collegium (COLL) Q1 2025: Jornay Scripts Up 24% as ADHD Expansion Outpaces Pain Portfolio
Jornay’s 24% prescription surge and expanded sales force signal a decisive pivot toward ADHD-driven growth, while the pain portfolio delivers durable cash flows to fund diversification and shareholder returns. With capital deployment discipline and a refreshed leadership team, Collegium enters 2025 positioned for further portfolio expansion and operational leverage.
Summary
- ADHD Franchise Acceleration: Jornay’s market share and prescriber base gains position it as the new growth engine.
- Pain Portfolio Stability: Core pain medicines provide durable cash generation and margin support.
- Capital Flexibility Rising: Strong cash flows and low leverage enable disciplined business development and buybacks.
Performance Analysis
Collegium delivered a robust first quarter with 23% revenue growth year over year, driven primarily by the ADHD therapy Jornay, which posted $28.5 million in net revenue and a 24% increase in prescriptions. This outpaced the overall ADHD market’s 5% to 6% growth, highlighting both share gains and effective commercial execution. The company’s pain portfolio—Belbuca, Xtampza ER, and Nucynta—remained stable, collectively generating $149.2 million in revenue, up 3% year over year, with each brand contributing low single-digit growth despite ongoing market contraction.
Operating expenses rose sharply, up 80% year over year, reflecting the scaling of the ADHD sales force and targeted investments in Jornay. However, non-GAAP adjusted EBITDA grew 3%, indicating Collegium’s ability to offset elevated spend with top-line expansion. Cash from operations reached $55.4 million, boosting the balance sheet to nearly $200 million in cash and equivalents, while net leverage declined to 1.5x and is expected to fall below 1x by year-end. The company reaffirmed its full-year guidance, projecting continued double-digit revenue and EBITDA growth, primarily on the back of Jornay’s momentum.
- ADHD Outperformance: Jornay’s 6.4 percentage point market share gain and 22% prescriber base growth signal strong competitive positioning.
- Margin Support from Pain Portfolio: Stable pain franchise cash flows offset script pressure and fund new investments.
- Capital Deployment: $16.1 million in debt repayment and a new $25 million accelerated share repurchase reflect focus on shareholder value and balance sheet strength.
The quarter marks a clear inflection as ADHD growth outpaces legacy pain assets, setting up Collegium for a diversified revenue mix and increased operational leverage as investments in Jornay begin to mature.
Executive Commentary
"As Collegium embarks on a new phase of growth, we remain committed to three very clear strategic priorities. First, to drive significant growth in Jornay APM. Second, to maximize the value of our pain portfolio. And third, to strategically deploy capital to further enhance shareholder value."
Vikram Karnani, President and Chief Executive Officer
"We are reaffirming our 2025 financial guidance. We expect net product revenues in the range of $735 to $750 million, an 18% increase year-over-year. This increase is primarily driven by Jornay, which we expect to generate net revenue in excess of $135 million, supported by continued performance across our pain portfolio."
Colleen Tupper, Chief Financial Officer
Strategic Positioning
1. ADHD Leadership: Jornay’s Differentiation and Commercial Scale
Jornay, ADHD therapy with evening dosing, is now Collegium’s lead growth driver. The sales force was expanded by 55 reps to 180, targeting 21,000 prescribers (up from 17,000). This expansion increases both reach and frequency, aiming to accelerate adoption and script growth, especially as back-to-school season approaches. Market research shows Jornay is the top-rated brand for all-day symptom control, and its unique profile is resonating with both prescribers and patients, fueling share gains from generic immediate-release competitors.
2. Pain Portfolio: Durable Cash Engine
The pain franchise remains Collegium’s financial foundation, with Belbuca, Xtampza ER, and Nucynta ER collectively representing over half of the branded extended-release opioid market. Despite broader market contraction, the portfolio’s revenue and cash flow stability support ongoing investment and margin protection. Patent exclusivity for key brands extends through at least 2027 for Nucynta and 2033 for Xtampza, providing visibility into future cash flows.
3. Capital Deployment and Portfolio Diversification
Management’s disciplined capital allocation approach is evident in rapid debt reduction, opportunistic share repurchases, and a continued appetite for business development. With net leverage expected to fall below 1x and nearly $200 million in cash, Collegium is positioned to pursue additional assets while maintaining financial flexibility. The board’s refresh and new executive hires further strengthen governance as the company eyes future M&A or product expansion opportunities.
4. Operational Leverage and Margin Trajectory
Operating expenses spiked due to Jornay investments, but management expects these costs to trend down in the second half of the year. As the expanded sales force productivity ramps and new marketing initiatives take hold, Collegium anticipates improved operating leverage and margin expansion in 2026 and beyond.
Key Considerations
This quarter underscores a strategic pivot toward ADHD-driven growth, while maintaining the pain portfolio’s cash-generating role. Investors should weigh the following:
Key Considerations:
- Jornay’s Prescription Momentum: Outperformance versus the ADHD market signals strong product-market fit and commercial execution.
- Sales Force Expansion: Increased rep headcount and target prescribers should drive further share gains, though impact will be more visible in late 2025 and 2026.
- Pain Portfolio Durability: Patent extensions and stable revenue provide a reliable base for future investment, but the segment faces ongoing market contraction and formulary headwinds.
- Capital Flexibility: Low leverage and strong cash flow generation enable both opportunistic M&A and continued shareholder returns through buybacks.
- Leadership and Board Refresh: Recent executive and board changes align with the company’s next phase of diversification and scale.
Risks
Key risks include potential ADHD market seasonality, which could temper near-term script growth ahead of the back-to-school surge, and ongoing price and volume pressure in the pain segment as the market contracts. Elevated operating expenses tied to commercial expansion may weigh on margins if top-line growth falters. While management notes minimal tariff exposure, regulatory and reimbursement changes in pain or ADHD could materially impact revenue and profitability.
Forward Outlook
For Q2 2025, Collegium guided to:
- Continued double-digit revenue growth, led by Jornay’s prescription acceleration and expanded sales force impact.
- Pain portfolio revenue stability, with modest script pressure offset by pricing and mix.
For full-year 2025, management reaffirmed guidance:
- Net product revenue of $735 to $750 million, up 18% year over year.
- Adjusted EBITDA of $435 to $450 million, up 10% year over year.
- Adjusted operating expenses of $220 to $230 million, with costs expected to decline in the second half as sales force investments mature.
Management highlighted several factors that will shape results:
- Full impact of the expanded ADHD sales force expected in late 2025 and 2026.
- Continued assessment of business development opportunities, with financial capacity to pursue meaningful transactions.
Takeaways
Collegium’s Q1 marks a decisive shift toward ADHD-led growth, with Jornay outpacing market trends and pain assets providing a stable foundation. Cash flow strength and prudent capital allocation support ongoing diversification and shareholder returns.
- Jornay’s Outperformance: Prescription and share gains validate the investment in commercial expansion and set up sustained leadership in ADHD.
- Pain Portfolio Resilience: Despite market headwinds, stable cash flows and patent protection underpin the company’s financial health.
- Watch for Execution on Business Development: With leverage falling and cash rising, the next strategic move could further reshape the portfolio and growth profile.
Conclusion
Collegium enters 2025 with clear momentum in ADHD and a resilient pain franchise, supported by strong cash flows, operational discipline, and a refreshed leadership team. The company’s ability to balance growth investments with capital returns and portfolio diversification will be the key watchpoint for investors as the year unfolds.
Industry Read-Through
Collegium’s pivot to ADHD and disciplined capital allocation offer a template for specialty pharma peers facing legacy product maturity and market contraction. The pronounced impact of sales force expansion and targeted digital marketing in driving share gains highlights the importance of commercial execution in crowded, genericized categories. Strong cash flow management and willingness to return capital to shareholders signal a maturing business model, while the focus on business development reflects industry-wide pressure to diversify and offset single-product risk. Other specialty pharma companies with concentrated portfolios or approaching patent cliffs may look to emulate Collegium’s approach to portfolio balancing, capital deployment, and leadership renewal as market dynamics intensify.